Should You Buy Roche Holdings AG Basel ADR Common Stock (RHHBY) in Drug Manufacturers

Roche Holdings AG Basel ADR Common Stock (RHHBY) is near the bottom in its industry group according to InvestorsObserver. RHHBY gets an overall rating of 10. That means it scores higher than 10 percent of stocks. Roche Holdings AG Basel ADR Common Stock gets a 8 rank in the Drug Manufacturers - General industry. Drug Manufacturers - General is number 124 out of 148 industries.

RHHBY has an Overall Score of 10. Find out what this means to you and get the rest of the rankings on RHHBY!

See Full RHHBY Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 10 would rank higher than 10 percent of all stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Roche Holdings AG Basel ADR Common Stock Stock Today?

Roche Holdings AG Basel ADR Common Stock (RHHBY) stock is trading at $33.75 as of 11:02 AM on Wednesday, Nov 29, an increase of $0.19, or 0.57% from the previous closing price of $33.56. The stock has traded between $33.65 and $33.79 so far today. Volume today is light. So far 1,063,782 shares have traded compared to average volume of 2,186,153 shares. Click Here to get the full Stock Report for Roche Holdings AG Basel ADR Common Stock stock.